Objective: To compare patient characteristics and treatment patterns among clobazam (CLB) and clonazepam (CZP)-treated patients with epilepsy in a longitudinal primary care database. Methods: In this pharmacoepidemiological study, real-life usage data from the Clinical Practice Research Database (CPRD) were evaluated. The CPRD collects data from approximately 690 primary care practices throughout the UK. Data included were from patients with ≥1 incident CLB or CZP prescription from 1995 to 2011 and were present in the database for ≥182 days prior to the index date (date patient was first prescribed CLB or CZP within the study period). Results: Of 21,099 patients who met inclusion criteria, 18.4% were receiving CLB and 81.6% were receiving CZP. More patients used CLB for epilepsy than CZP (76.1% vs 8.7%). CLB-treated adults (≤18 years) were younger than those treated with CZP (41.0 vs 48.2 years; p < 0.001), while CLB-treated children (≤18 years) were older than those treated with CZP (8.8 vs 7.3 years, p < 0.001). The median CLB dosage did not change from baseline to last follow-up, while median CZP dosage increased 25% in adults and 50% in children. Median treatment duration, as well as retention rate up to 10 years, was similar between CLB and CZP in each age group. Conclusions: Among adult and pediatric patients in the UK, CLB is more often prescribed for epilepsy than CZP. The median CLB dosage used by both adults and children remained stable over the 16-year study period, while the median CZP dosage increased in both adults and children.
Introduction
Benzodiazepines (BZDs) have been used to treat a variety of disorders, including anxiety, depression, insomnia, alcohol withdrawal, and seizures. While BZDs are the most commonly prescribed class of psychotropic medications (Olfson et al., 2015) , select few are used to treat epilepsy: diazepam and lorazepam for seizure emergencies; midazolam for refractory status epilepticus and seizure emergencies; nitrazepam for myoclonic seizures, infantile spasms and other childhood seizures; clorazepate, clonazepam and clobazam for long-term epilepsy management (Riss et al., 2008; Schatzberg and Nemeroff, 2009) . Though BZDs are the drugs of first choice for seizure emergencies (De Waele et al., 2013) , their use as maintenance treatments declined over recent decades due to concerns regarding potential for abuse, tolerance, excessive sedation and cognitive decline with chronic use (Olfson et al., 2015; Paterniti et al., 2002; Sankar et al., 2014; Stewart, 2005) . The availability of several new antiepileptic drugs (AEDs) for maintenance therapy also reduced BZD use for epilepsy.
The BZDs clobazam (CLB; Onfi ® , Deerfield, IL, US) and clonazepam (CZP; Klonopin ® , San Francisco, CA, US) have been used worldwide since the 1970s. CZP is approved in the EU for all forms of epilepsy and for panic attacks in adults, and in the US for panic disorder and as mono-or adjunct therapy in a broad range of seizure disorders, including Lennox-Gastaut syndrome (LGS). CLB has been successfully used for many years in the EU as both an AED and an anxiolytic, but was approved only recently in the US (October 2011) for the adjunctive treatment of seizures associated with LGS in patients ≥2 years (Ng et al., 2011) .
As use of CLB in the EU has been well established, data from the UK-based Clinical Practice Research Datalink were evaluated to compare real-world use of CLB versus CZP for epilepsy.
Methods

Data source
The Clinical Practice Research Datalink (CPRD), which furthers the research developments of the General Practice Research Database (GPRD) (Lawson et al., 1998) , comprises more than 62 million patient-years of data collected from approximately 10 million patients throughout the United Kingdom (UK). It is the largest computerized database of anonymous, longitudinal, primary care clinical records. CPRD data, which are currently being collected from 690 primary care practices, are directly generated by computer from general practitioner (GP) practices equipped with specialized software. Data from the CPRD have been extensively used in over 890 clinical reviews and papers, including numerous pharmacoepidemiological studies. The principal information available for analysis includes patient demographics, prescriptions of medicine, clinical diagnoses, hospital or specialist referrals, and laboratory test results (Garcia Rodriguez and Perez Gutthann, 1998; Wood and Martinez, 2004) .
Study design and inclusion criteria
In this historical, longitudinal, incident-user (Johnson et al., 2012) cohort study, patient data were obtained from the externally validated CPRD database (Jick et al., 1991; Jick et al., 2003) . Epilepsy patients who had at least one incident prescription of CLB or CZP within the study period (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) were included in the analysis (Fig. 1 ). To ensure patients had not been previously prescribed CLB or CZP, patient data must have been present in the database for at least 182 days prior to the index date and without any prescription for CLB or CZP. The index date is defined as the date of first CLB or CZP prescription within the study period.
Patient characteristics and treatment patterns evaluated
The primary objectives were to evaluate demographic characteristics and treatment patterns between patients prescribed CLB and those prescribed CZP. Demographics and baseline characteristics for patients with epilepsy included age, sex, drug dosage, and concomitant AED use. Patients with an epilepsy diagnosis at the index date were those who had at least one record with an epilepsy diagnosis any time prior to the index date or within 90 days following the index date. Primary AEDs of interest were selected according to the National Institute for Health and Care Excellence (NICE) clinical guidelines regarding the management of epilepsy and grouped according to the British National Formulary (BNF) classification system.
Characteristics of patients with epilepsy at follow-up included time of follow-up, treatment duration, and drug dosage. Drug dosage was not directly available in the database and was therefore computed at the last prescription date using the following formula: dosage = substance strength × numeric daily dosage (NDD), where NDD corresponds to number of pills/tablets/milliliters per day. No imputation was performed when NDD was 0 or missing.
The evaluation of the development of dependence was a secondary objective of the study. Drug dependency cases were identified by the presence of one record with a drug dependence diagnosis (Read code: E24*-Drug dependence, Eu19211-[X] Drug addiction NOS) or a drug dependence detoxification (Read code: 8BA9*-Detoxification dependence drug) during follow-up. Patients with a history of drug dependency before treatment initiation were not included in this analysis.
Statistical analysis
Statistical comparisons between CLB-and CZP-treated groups were performed using the student t test for continuous variables and either the X 2 or Fisher exact tests for categorical variables. For treatment duration and analysis of drug dependence, curves were drawn using the Kaplan-Meier method and statistical comparisons were performed using the log-rank test. For the analysis of drug dependence, the incidence rate per person year was also calculated:
Incidence rate / person-year = Number of patients with drug dependency Total time of exposure to treatment for all patients (years)
Standard protocol approvals, registrations, and patient consents
All research undertaken using data obtained from CPRD is approved by, as appropriate, an ethics committee, a scientific committee, and the National Information Governance Board Ethics and Confidentiality Committee. Protocol 13 043R entitled "Treatment Patterns in Patients With Epilepsy in Primary Care in the UK" was approved April 3, 2013 by the Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare Products Regulatory Agency (MHRA) Database Research for CPRD.
Results
CPRD patient population
Of 21,099 patients who met inclusion criteria, 3882 (18.4%) received CLB and 17,217 (81.6%) received CZP (Fig. 1) . Overall, CLB was more widely used for the treatment of epilepsy than CZP as 76.1% of patients received CLB for epilepsy, while only 8.7% of patients received CZP for epilepsy (Fig. 1 ).
Adult patients with epilepsy
Baseline characteristics
In the CPRD database, 2312 adults (≥18 years) with epilepsy had received CLB and 1268 had received CZP (Table 1) . A greater percentage of adults with epilepsy were women, but the femaleto-male patient ratio was the same in either treatment group. On average, CLB-treated adults were younger than those treated with CZP (41.0 vs 48.2 years, respectively; p < 0.0001). The median (range) CLB dose was 10.0 mg (5.0-60.0); the median (range) CZP dose was 0.8 mg (3.0-8.0). A significantly greater percentage of CLB-treated adults were receiving concomitant AEDs than those treated with CZP (93% CLB vs 79% CZP; p < 0.0001). Significantly fewer CLB-treated adults used concomitant BZDs (eg, diazepam) than those receiving CZP (9% CLB vs 12% CZP; p = 0.002). The most commonly used concomitant AEDs (≥15%) among both treatment groups were carbamazepine (30%), sodium valproate (29%), lamotrigine (28%) and levetiracetam (20%).
Follow-up characteristics
The average time of follow up for both CLB-and CZP-treated patients was similar and greater than 5 years (5.5 years CLB vs 5.2 years CZP; Table 2 ). The median CLB dosage did not change from baseline to last follow-up, while median CZP dosage increased 25% (Tables 1 and 2 ). The median duration of treatment was similar between CLB and CZP (28.3 months CLB vs 27.5 months CZP; Fig. 2 ). Retention rates up to 10 years were similar between CLB-and CZPtreated patients.
Children with epilepsy 3.3.1. Baseline characteristics
In the CPRD database, 574 pediatric patients (<18 years) with epilepsy had received CLB and 171 had received CZP (Table 1) . A greater percentage of children with epilepsy were males, but the ratio of male-to-female patients was the same in either treatment group. CLB-treated pediatric patients were older than those treated with CZP (8.8 vs 7.3 years, p < 0.001). The median (range) CLB dose was 20.0 mg (5.0-60.0); the median (range) CZP dose was 1.0 mg (0.3-7.5).
A comparable number of CLB-and CZP-treated children were receiving concomitant AEDs (92% CLB vs 89% CZP; p = 0.18), including BZDs (9% vs 10%; p = 0.73). The most commonly used concomitant AEDs (≥15%) in either pediatric treatment group were sodium valproate (40%), lamotrigine (30%), carbamazepine (20%) and topiramate (16%).
Follow-up characteristics
Children treated with CLB had a shorter follow-up period than those treated with CZP (5.5 vs 6.3 years; p = 0.027). The median CLB dosage did not increase from baseline to last follow up, while the median CZP dosage increased 50% (Tables 1 and 2 ). The median treatment duration was similar between groups (34.6 months CLB vs 31.2 months CZP; Fig. 3 ). Retention rates up to 10 years were similar between treatment groups.
Dependence analysis for patients with epilepsy: all ages
A total of 26 CLB-and CZP-treated patients (13 in each treatment group: 0.5% CLB, 0.9% CZP) had a confirmed drug dependency diagnosis, indicating a 1.6 and 3.3 incidence rate (per 1000 person-year) in the respective treatment groups. Overall, at least 11 patients were identified as having benzodiazepine dependence, though the particular type of BZD was not specified in the database. The likelihood of patients remaining free of drug dependency over a 5-year treatment period was 99.4% among CLB-treated patients and 98.5% among CZP-treated patients (Fig. 4) . The incidence rate per 1000 Patient Year Exposure was 1.55 among CLB-treated patients and 3.29 among CZP-treated patients.
Discussion
In addition to the treatment of anxiety and other disorders, both CLB and CZP have long been used in Europe for the treatment of epilepsy, primarily idiopathic generalized and partial epilepsy. While concerns over safety with both acute treatment (eg, sedation, psychomotor and cognitive impairment) and chronic use (tolerance, withdrawal syndrome) (Lader, 2008; Paterniti et al., 2002) should be considered when making treatment decisions, the benefits of BZDs for epilepsy appear to outweigh the risks for many patients, including children (Conry et al., 2014; Mehndiratta et al., 2003; Montenegro et al., 2001; Silva et al., 2006) .
In the longitudinal cohort study of data from the UK-based CPRD presented here, patient characteristics and treatment patterns for CLB and CZP use from 1995 to 2011 were evaluated in both adult (≥18 years) and pediatric patients (<18 years). Overall, CLB was more widely used for the treatment of epilepsy than CZP (76.1% vs 8.7%, respectively). These results mirror the trend observed in a previously conducted primary care cohort study that evaluated AED utilization in the UK from 1993 to 2008 (Nicholas et al., 2012) . In that study, CLB use exceeded CZP use by the end of the study period (CLB: 2.2% person-years in 1993-3.3% in 2008; CZP: 2.6% personyears in 1993-2.9% in 2008), though both drugs were among the less frequently prescribed AEDs overall (Nicholas et al., 2012) .
Because of its unique 1,5 chemical structure, receptor binding properties, and clinical effects, CLB may offer an improved safety profile over the 1,4-BZDs, as well as sustained efficacy that may not be evident with other BZDs used to treat epilepsy (Riss et al., 2008; Wheless and Phelps, 2013) . CLB is highly selective for the subunit of the GABA A receptor that is associated with antiepileptic activity (␣2) with less affinity toward the subunit that is known to contribute to sedation (␣1), while CZP is nonselective for either subunit (Jensen et al., 2014) . Furthermore, though the exact manner in which tolerance can occur with particular BZDs remains to be determined, the differential expression of GABA A receptor subunits in the brain and the variable affinities of BZDs for those subunits a Number of patients still on follow-up and for whom no events have occurred have been implicated in the mechanisms underlying tolerance with BZDs (Sankar, 2012; Vinkers and Olivier, 2012; Vinkers et al., 2012) .
Differences in the mechanism of action between CLB and CZP could explain the median dosage increase observed in CZP-treated patients that was not apparent in CLB-treated patients in this study. From baseline to the follow-up period, the median CLB dosage did not increase for either patient population, while the median CZP dosage increased 25% in adults and 50% in children. As the initial dosages of CLB and CZP appeared to be equivalent (10-15 mg/day CLB:1 mg/day CZP) (Sankar et al., 2014) , these results suggest that there was a therapeutic need to increase the CZP dose over time, possibly due to loss of efficacy, and perhaps indicating the development of tolerance to CZP that was not observed with long-term CLB use. Indeed, a loss of efficacy in approximately 30% of CZPtreated patients within 3 months of use has been suggested (Bacia et al., 1980; Pinder et al., 1976 ), yet CLB use over a period of 3 years has resulted in sustained improvements in drop-and total seizures in patients with LGS (Conry et al., 2014) . Similarly, although the analysis of dependence using dependence diagnosis is likely to lack sensitivity, the higher incidence of dependence diagnosis for CZP versus CLB further supports a possible difference in tolerance profile between the drugs. A difference in tolerance between CLB and CZP treatment can have important clinical implications: CZP may be more appropriate for shorter-term use for non-epilepsyrelated disorders, while clobazam may be considered an effective, long-term therapy for various forms of epilepsy.
Overall, CLB-treated adults in this study were receiving more concomitant AEDs than CZP-treated adults, an observation that may be attributed to the fact that CLB is primarily used as an adjunctive epilepsy therapy in the UK. A less likely explanation is that such differences in AED usage might indicate greater disease severity among those in the CLB group or possibly reflect variable use of these two BZDs for different types of epilepsy; such conclusions cannot be made without additional patient information and analyses. Though the CPRD database is broadly representative of the UK population, there are some inherent limitations of this database including the possibility of missing data (which may be due to the inability to capture prescriptions from neurologists), a lack of consideration for confounding effects, and the inability to identify the type of epilepsy for which patients are receiving either CLB or CZP.
The median treatment duration was similar between CLB-and CZP-treated groups in both adult and pediatric populations, but the follow-up period was slightly shorter for CLB-treated children compared to their CZP-treated counterparts (5.5 vs 6.3 years). The reason for the slight variation in length of follow-up among the CLB-and CZP-treated pediatric population is unclear, as is the cause for the opposing pattern of CLB vs CZP use by age: adult patients treated with CLB for epilepsy were younger than those treated with CZP, while CLB-treated children were older than their CZP-treated counterparts. These results may simply reflect variability in patient care among the physicians in the UK who issue the majority of longterm prescriptions and manage the continuity of AED treatments.
Future directions
Further analysis of the CPRD database supplemented with data from a managed care database could include comparisons of AED effectiveness through an evaluation of surrogates for effectiveness, such as rates of hospitalizations, in-patient and out-patient office visits, as well as changes in AED prescriptions (dosage changes, newly added medications).
Conclusions
In the UK, stable doses of CLB have been used for years-primarily for the treatment of epilepsy in both adult and pediatric patients-while CZP use in epilepsy is limited. An increase in the median dose of CZP used was evident in the 16-year study period, but no such dose increase was observed in patients treated with CLB. The results from this study suggest that UK physicians prefer CLB over CZP for the treatment of epilepsy.
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